TheraRadar
← Back
Data updated: Mar 29, 2026

HYBIO

CardiovascularNeurologyOncology
Generics

HYBIO is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.

2020
Since
2
Drugs
-
Trials
13
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

GLATIRAMER ACETATE 2026-02-11
GLATIRAMER ACETATE 2026-02-11
GLATIRAMER ACETATE 2025-12-31
EPTIFIBATIDE 2025-06-13
Labeling
GLATIRAMER ACETATE 2025-05-16
Labeling
GLATIRAMER ACETATE 2025-05-16
Labeling
GLATIRAMER ACETATE 2025-05-07
EPTIFIBATIDE 2025-03-25
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 46%
1 drugs
Neurology 46%
1 drugs
Oncology 8%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

GE HEALTHCARE specialty
Neurology, Cardiovascular, Oncology
Novo Nordisk big-pharma
Oncology, Cardiovascular, Neurology
Novartis big-pharma
Oncology, Cardiovascular
AZURITY specialty
Cardiovascular, Oncology, Neurology
Merck big-pharma
Oncology, Cardiovascular